Related Experiment Video
Updated: Jul 16, 2025

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Hepatitis-B virus: replication cycle, targets, and antiviral approaches
Nour Nasser1, Pierre Tonnerre2, Abdellah Mansouri1
1Université Paris-Cité, Centre de recherche sur l'inflammation, Inserm U1149, Paris, France; Department of Hepatology, AP-HP, Hôpital Beaujon, Clichy, France.
Insights
Hepatitis-B virus (HBV) infection affects millions, causing liver cancer. Current treatments require lifelong therapy, but new antiviral drugs and immunotherapies offer hope for a potential cure.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis-B virus (HBV) infection is a significant global health issue, with 257 million chronic carriers and 1 million annual deaths, primarily from hepatocellular carcinoma (HCC).
- Current nucleotide analog treatments improve prognosis and reduce HCC risk but necessitate lifelong adherence.
- Understanding HBV replication and host immune responses is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To review the HBV replication cycle.
- To summarize current treatment modalities for HBV infection.
- To discuss emerging antiviral targets and therapies aimed at achieving an HBV cure.
Main Methods:
- Literature review of HBV replication, pathogenesis, and treatment strategies.
- Analysis of ongoing clinical trials and preclinical research on direct-acting antivirals (DAA) and immunomodulatory therapies.
- Synthesis of information on potential drug targets and novel antiviral approaches.
Main Results:
- HBV replication involves complex interactions between viral proteins and host cellular machinery.
- Nucleotide analogs offer long-term control but not a definitive cure.
- Combination therapies, including DAAs and immunomodulation, show promise for increased cure rates.
Conclusions:
- Achieving a functional cure for HBV remains a significant challenge.
- Further research into HBV's life cycle and host immunity is essential for identifying new therapeutic targets.
- Novel antiviral strategies and combination therapies represent the most promising path towards a curative treatment for chronic HBV infection.
Abstract:
An estimated 257 million people are chronic carriers of hepatitis-B virus (HBV) infection, which resulted in around 1 million deaths, mainly due to hepatocellular carcinoma (HCC). Long-term nucleotide analog treatment of HBV infection is associated with favorable prognosis, no disease progression, and a reduction of HCC risk, but lifelong treatments are required. A better understanding of HBV replication cycle and the host immune response will likely improve the identification of new targets for drug development. Studies are ongoing to determine if it is possible to successfully combine direct-acting antivirals (DAA) with an immunomodulatory therapy to allow increased cure rates. This review will start with summarizing the HBV replication cycle, recall current treatments, and then discuss potential targets and antiviral approaches in development to optimistically reach the HBV cure.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Viruses with RNA Genomes
Viral Replication: Lytic Cycle
Viral Replication: Lysogenic Cycle
What are Viruses?
Lysogenic Cycle of Bacteriophages

